Big mergers and acquisitions are currently off the table for Monsanto, following the company’s failed bid for Syngenta last year, said Hugh Grant, the ag giant’s chairman and chief executive. Instead, the company plans to use smaller-scale M&A deals to boost its growth in the crop protection space.
“We will not and we would not have done an overpriced deal. So, I think, now, we are looking at how we get to the same destination, but using a different path,” Grant said on a conference call following Monsanto’s second-quarter earnings report on Wednesday. “And I think the way of getting there is going to be driven more on a product-by-product basis. It’s going to be driven by collaboration, bringing other people’s chemistry up on that acre. And I think it’s going be driven by some of the work that we underscored this morning like the new nematicide from Nemastrike and frankly some of the new smaller companies out there like Nimbus Therapeutics.”
格兰特说，他继续看到数据科学领域不断扩大的机会。
“We still believe there’s an opportunity for the integrated solutions. We still think there is an opportunity in bringing chemistry and biology together on that acre and using data science as the glue that holds that together. So, that’s been unwavering.”
孟山都周三早些时候发布 第二季度销售和收益疲软 与一年前相比，由于农业生产力领域的草甘膦下降，美国玉米和大豆的折扣增加，美国季节开始较慢导致大豆销量下降，预计播种面积减少，以及玉米销售成本上升由于上一年较小的生产计划。